A philosophical thought about clinical development in oncology: what if we cared more about the patients excluded from most clinical trials? Rare cancers, patients with common tumors but rare mutations, and many others are left aside by the crowd of studies. For oncology startups, focusing on these patients could be a winning and distinctive strategy, the strategic advantages for the PoC are real. Alain Rinaldi #RareCancers #OncologyClinicalTrials
MEDExpansion
Biotechnology Research
Lausanne, Vaud 72 followers
Fractional CMO for early-stage oncology startups. We help shape compelling clinical business cases to win funding
About us
▶️ MEDExpansion is a Swiss consulting company founded in 2014 in Lausanne, Switzerland. The founder and CEO is Dr Alain Rinaldi, an oncologist with an outstanding vision of the whole process of drug development in oncology. ▶️ We help companies with preclinical projects in oncology build the path from preclinical to clinical POC. Importantly, our global medical vision help incorporate in this construction the elements of the future medical environment to give the project its highest possible value for investors. ▶️ Delivering high-end, tailor-made advisory is the core value that drives our work. We flexibly operate with short-term, flash assignments or longer-term collaborations.
- Website
-
http://www.medexpansion.ch
External link for MEDExpansion
- Industry
- Biotechnology Research
- Company size
- 1 employee
- Headquarters
- Lausanne, Vaud
- Type
- Privately Held
- Founded
- 2014
- Specialties
- Proof-of-concept protocols, Biotechs, Medical, Medical strategy, Development of networks, immuno-oncology, Clinical development plan, TPP, Oncology, Phase 1/2 protocols, Medical advisor, startup, oncology, FIH, and Chief medical officer
Locations
-
Primary
Get directions
Avenue Floréal 3
Lausanne, Vaud 1006, CH
Employees at MEDExpansion
Updates
-
In today’s tough fundraising environment, I found an encouraging insight in this article recently published in the Harvard Business Review. Harvard Business Review MEDExpansion #OncologyStartups #FundRaising #Innovation Combining for unconventionality: when resource constraints may promote innovation capabilities. H. Ketkar, M. Roche (HBS Strategy Unit, working paper 25-032, sept 2025)
-
The CMO’s perspective: both spectator and actor in the dialogue with investors. Alain Rinaldi MEDExpansion
At seed and Series A meetings, R&D teams and investors look through different lenses: science on one side, market on the other. As CMO, my role is to help build the bridge, so that both sides meet, find common ground, and move projects forward together. MEDExpansion #InvestorMeetings #StartupPitch #SeedFunding #OncologyInvestors # EarlyStageCMO
-
Immunotherapy has changed the game. What used to be replacing modest last-line chemotherapy is now a direct challenge against immunotherapies that often deliver robust efficacy and long remissions to patients. For startups, this means strategies must evolve eg finding smarter ways outside the crowded highways to de-risk the path to proof of concept. MEDExpansion #OncologyClinicalDevelopment #OncologyImmunotherapy #OncologyStartups
Immunotherapy has changed the game. What used to be replacing modest last-line chemotherapy is now a direct challenge against immunotherapies that often deliver robust efficacy and long remissions to patients. For startups, this means strategies must evolve eg finding smarter ways outside the crowded highways to de-risk the path to proof of concept. MEDExpansion #OncologyClinicalDevelopment #OncologyImmunotherapy #OncologyStartups #OncologyChallenges